This World Diabetes Day, we at the American Association of Clinical Endocrinology (AACE) extend our support to those in the endocrine care team who help diabetes patients every day. Now with a new brand and name that more clearly defines AACE as a community of individuals who work together to elevate the practice of clinical endocrinology, we are committed to expanding diabetes education with a more inclusive approach — with endocrinologists leading the way.
Lilly has launched “Insulin Affordability: Learn. Act. Share.” to encourage those who use Lilly insulin to:
Learn about our affordability options
Act by visiting insulinaffordability.com or calling the Lilly Diabetes Solution Center
Share this important information with others who may benefit from our solutions.
Anyone with commercial insurance, and those without insurance at all, can continue filling their monthly prescription of Lilly insulins for $35 through this program.
The U.S. Food and Drug Administration (FDA) approved two additional doses of Eli Lilly and Company's (NYSE: LLY) Trulicity® (dulaglutide). The approval expands the label of once-weekly Trulicity to include 3.0 mg and 4.5 mg doses based on data from AWARD-11. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 mg in people with type 2 diabetes.
A new $35 co-pay is available through the Lilly Insulin Value Program in response to the COVID-19 crisis in the U.S.
At this time, the leading pharmaceutical manufacturers are reporting that COVID-19 is NOT having an impact on their manufacturing and distribution capabilities for insulin and other related supplies.
August 18, 2020 (Latest Update)
AACE is closely monitoring developments regarding COVID-19 and working with partner medical societies to provide information and resources to our members. Click to view COVID-19 resources, including more about navigating telehealth services.
As the coronavirus (COVID-19) continues to spread in the United States, it is important for everyone to take the necessary precautions to help prevent infection and spread of the virus. While it is difficult to assess the unique implications of COVID-19 in people with diabetes (type 1, type 2, or gestational) at this time, diabetes and other chronic medical conditions can make patients more vulnerable to infections, leading to serious consequences. In addition, uncontrolled diabetes with hyperglycemia is known to impair immune function.
The FDA has identified this as a Class I recall, the most serious type of recall. Use of these devices may cause serious injuries or death. Click to read which models are affected.
February 3, 2020
The AACE diabetes algorithm is a comprehensive management algorithm that covers lifestyle, obesity, prediabetes, lipids, hypertension and glucose management strategies.
August 8, 2019
The CDC recently launched in collaboration with Google Health, a prediabetes quiz that will pop up when end users search for certain medical information using their Google browser to bring more public awareness about prediabetes.
Medscape reports the nasal powder, used in the treatment of severe hypoglycemia for patients aged 4 years or older, is the first licensed glucagon product that is not delivered by injection and that does not require a multistep mixing process.
Presenting PrescriptionHelp.aace.com – A directory of prescription affordability programs and resources for your endocrine patients to help them acquire the medications they need at reduced out-of-pocket costs.
The U.S. Food and Drug Administration is warning patients and health care providers that certain Medtronic MiniMed insulin pumps are being recalled due to potential cybersecurity risks.
Findings presented at the AACE 28th Annual Scientific & Clinical Congress showed that seeking hospital care for diabetic ketoacidosis during the weekend as opposed to during the week may increase mortality risk.
April 25, 2019
Type 2 diabetes (T2D) is associated with increased risk for fractures in the short term but not in the long term, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
Treatment with linagliptin in patients with type 2 diabetes (T2D) and cardiovascular and/or kidney disease had no impact on risk for cardiovascular or kidney events or hospitalization for heart failure, according to results of the CARMELINA study (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus) presented at the AACE 28th Annual Scientific & Clinic
Abaloparatide followed by alendronate treatment may improve bone mineral density (BMD) in women with postmenopausal osteoporosis and type 2 diabetes (T2D), according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
A weighted cardiometabolic disease staging risk score can be used to quantify race- and sex-specific type 2 diabetes risk in a large, diverse population, according to study results presented at the AACE 28th Annual Scientific & Clinical Congress.
The cardiovascular and renal effects of treatment with canagliflozin in patients with type 2 diabetes are more prominent in patients not taking metformin compared with patients treated with canagliflozin as an add-on to metformin, according to data from the CANVAS (CANagliflozin cardioVascular Assessment Study) Program presented at the AACE 28th Annual Scientific & Clinical Congress.
AACE Member Roy Taylor, MD, discussed the pathogenesis of hepatic insulin resistance in people with type 2 diabetes in an interview at AACE’s 28th Annual Scientific & Clinical Congress.